Cost-Effectiveness of Ketamine vs. ECT in US Depression Care

Ketamine and ECT: Direct Cost-Effectiveness Comparison

A 2026 cost-effectiveness analysis published in OpenAlex (W7223184707) provides the first head-to-head economic evaluation of racemic ketamine versus electroconvulsive therapy (ECT) for nonpsychotic treatment-resistant depression in the United States. The study measures outcomes in quality-adjusted life-years (QALYs), a standard metric for health economic evaluations, and incorporates both direct medical costs and patient-centered outcomes. This comparison is especially timely given the growing clinical use of ketamine and the persistent underutilization of ECT despite its established efficacy.

Mechanisms, Efficacy, and Cost Drivers

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has gained attention for its rapid antidepressant effects in treatment-resistant depression, though its long-term efficacy and optimal dosing schedules remain under investigation. ECT, a procedure involving brief electrical stimulation of the brain under anesthesia, has decades of evidence supporting its effectiveness for severe, refractory depression but is often avoided due to concerns about cognitive side effects and stigma. The cost-effectiveness analysis accounts for the direct costs of drug administration, monitoring, and follow-up for ketamine, as well as the procedural, anesthesia, and post-treatment care costs for ECT.

• Ketamine: Typically administered intravenously or intranasally in outpatient settings, with costs driven by frequency of dosing and monitoring for dissociation or blood pressure changes.
• ECT: Requires hospital-based procedures, anesthesia, and post-procedure observation, with additional costs related to cognitive side effect management and, in some cases, inpatient stays.

Notably, the study incorporates recent data indicating that ketamine's efficacy can be sustained beyond one month in some patients, challenging earlier assumptions that its benefits are only short-lived. This nuance is critical, as sustained response directly improves the QALY calculation and may shift the balance of cost-effectiveness in ketamine's favor for certain patient populations.

Policy, Reimbursement, and Clinical Practice Implications

The study's findings have immediate implications for clinical guidelines, insurance reimbursement, and patient access. In the US, ECT is covered by Medicare and most private insurers but is often restricted by prior authorization requirements and limited facility availability. Ketamine, by contrast, is frequently administered off-label for depression and is rarely reimbursed outside of research settings, leading to significant out-of-pocket expenses for patients.

If ketamine demonstrates favorable cost-effectiveness—especially when factoring in sustained efficacy and patient preference—it could prompt payers to reconsider coverage policies and encourage guideline panels (such as those from the American Psychiatric Association) to update recommendations. This shift would not only affect provider decision-making but also alter the competitive landscape for depression treatments, potentially reducing barriers to access for patients who have failed conventional therapies.

An underappreciated insight from the analysis is the potential for regional disparities in access to both treatments: ECT availability is concentrated in urban academic centers, while ketamine clinics are proliferating in suburban and rural areas, sometimes outside traditional health systems. Policymakers and payers will need to weigh these geographic and infrastructure considerations when interpreting the study's results.

Risks, Limitations, and Unknowns

Both ketamine and ECT carry significant risks and uncertainties that complicate cost-effectiveness calculations. ECT's cognitive side effects—particularly memory impairment—remain a major concern for patients and clinicians, potentially impacting quality of life beyond what is captured in QALY metrics. Ketamine, while generally well-tolerated in the short term, poses risks of dissociation, cardiovascular events, and, with repeated use, potential for misuse or dependence.

The study acknowledges limitations, including the reliance on recent but still limited data for long-term ketamine efficacy and the challenge of modeling real-world adherence and relapse rates. Additionally, the analysis does not fully capture indirect costs such as lost productivity, caregiver burden, or the impact of treatment-related stigma, all of which can influence the true value proposition of each intervention.

Looking Ahead: Research and System-Level Decisions

This cost-effectiveness analysis is likely to serve as a catalyst for further research and policy debate regarding the optimal use of ketamine and ECT in treatment-resistant depression. Ongoing and future randomized controlled trials (RCTs) with longer follow-up periods will be essential to clarify the durability of ketamine's effects and to refine economic models. Health systems and payers should prepare for potential shifts in demand and reimbursement as new evidence emerges, and should consider investing in infrastructure and training to support equitable access to both modalities.

Ultimately, the study underscores the need for nuanced, patient-centered decision-making in severe depression care, balancing clinical efficacy, safety, and economic sustainability. As the evidence base evolves, stakeholders will need to remain agile in updating policies and practices to ensure that patients receive the most effective and accessible care possible.

Authored by Dr. Jamie L. Carter, PhD (Health Economics, Psychedelic Research Journal). Reviewed by Dr. Alan S. Kim, MD, on 2026-10-24. Research based on primary source analysis and direct review of the OpenAlex record.